AstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an irritable bowel syndrome drug in
The FDA has fast-tracked AstraZeneca’s Farxiga (dapagliflozin) as a treatment to reduce risk of cardiovascular death, or worsening of heart failure, in adults with reduced or preserved ejec
Ahead of the eyeforpharma Awards we spoke to judge Jennifer Wong – AstraZeneca’s senior director, RWE strategy & alliances, global medical affairs – about why collaboration and RWE
Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
